ADAMAS PHARMACEUTICALS INC's ticker is ADMS and the CUSIP is 00548A106. A total of 87 filers reported holding ADAMAS PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $107,000 | -29.1% | 20,995 | -0.7% | 0.00% | – |
| Q1 2019 | $151,000 | -6.2% | 21,149 | +12.5% | 0.00% | – |
| Q4 2018 | $161,000 | -52.2% | 18,796 | +11.9% | 0.00% | – |
| Q3 2018 | $337,000 | -63.2% | 16,795 | -52.7% | 0.00% | -100.0% |
| Q2 2018 | $917,000 | +43.3% | 35,507 | +32.8% | 0.00% | 0.0% |
| Q1 2018 | $640,000 | -25.5% | 26,743 | +5.6% | 0.00% | 0.0% |
| Q4 2017 | $859,000 | +23.2% | 25,335 | -22.9% | 0.00% | 0.0% |
| Q3 2017 | $697,000 | +152.5% | 32,878 | +95.5% | 0.00% | – |
| Q3 2016 | $276,000 | -48.1% | 16,817 | -52.1% | 0.00% | -100.0% |
| Q2 2016 | $532,000 | -15.8% | 35,116 | -19.6% | 0.00% | 0.0% |
| Q1 2016 | $632,000 | +191.2% | 43,682 | +470.0% | 0.00% | – |
| Q4 2015 | $217,000 | -23.3% | 7,664 | -54.7% | 0.00% | – |
| Q3 2015 | $283,000 | -40.2% | 16,914 | -6.3% | 0.00% | – |
| Q2 2015 | $473,000 | – | 18,053 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| C Partners Holding GmbH | 1,474,482 | $38,661,000 | 18.12% |
| GREAT POINT PARTNERS LLC | 772,600 | $20,258,000 | 7.90% |
| BOW STREET LLC | 126,870 | $3,327,000 | 1.61% |
| Opaleye Management Inc. | 150,000 | $3,933,000 | 1.56% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 316,690 | $8,304,000 | 0.64% |
| WALL STREET ASSOCIATES | 225,000 | $5,899,000 | 0.56% |
| Granite Point Capital Management, L.P. | 61,813 | $1,621,000 | 0.47% |
| EMERALD ADVISERS, LLC | 348,721 | $9,143,000 | 0.44% |
| TFS CAPITAL LLC | 97,652 | $2,560,000 | 0.25% |
| Spark Investment Management LLC | 59,300 | $1,553,000 | 0.22% |